Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director | May 20, 2026 | May 21, 2026 |
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Director | June 16, 2026 | June 17, 2026 |
| MARINUS PHARMACEUTICALS, INC.MRNS · Entity 83359 | Director | January 17, 2017 | January 19, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INOVIO PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2036-05-20 | Direct | 41,800 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 41,800 · Balance 41,800 F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2: Options to vest 100% on May 20, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 34,200 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 34,200 · Balance 34,200 F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.
F2: Options to vest 100% on May 20, 2027.
F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.
IRONWOOD PHARMACEUTICALS INC
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 235,036 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 63,481 · Balance 235,036 F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
MARINUS PHARMACEUTICALS, INC.
Report date January 17, 2017 · Filed January 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2027-01-17 | Direct | 10,500 |
Reported balance
After 2017-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-17 · Grant · Acquired 10,500 · Balance 10,500 F1: Options to purchase shares of common stock vest in 12 equal monthly installments commencing 1/31/17. |
| Restricted stockSEC Table II · derivative / convertible security | Direct | 4,500 |
Reported balance
After 2017-01-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-17 · Grant · Acquired 4,500 · Balance 4,500 F2: Each share of restricted stock represents the right to receive, at settlement, one share of common stock. F3: All shares of restricted stock vest on 1/17/18. F4: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase shares of common stock vest in 12 equal monthly installments commencing 1/31/17.
F2: Each share of restricted stock represents the right to receive, at settlement, one share of common stock.
F3: All shares of restricted stock vest on 1/17/18.
F4: Not applicable.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aravive, Inc.
Report date April 08, 2020 · Filed April 09, 2020
Section 16 reporting ended · disclosed 2020-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,201 |
Reported balance
After 2020-04-08 transaction · row 1
1 source rowRow 1 · 2020-04-08 · Disposition to issuer · Disposed 9,291 · Balance 61,201 F1: The reporting person resigned his position as Chairman of the Board of Directors of Aravive, Inc., effective April 8, 2020, resulting in the forfeiture of 9,291 shares of common stock issuable upon the vesting of certain restricted stock units previously granted on December 20, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person resigned his position as Chairman of the Board of Directors of Aravive, Inc., effective April 8, 2020, resulting in the forfeiture of 9,291 shares of common stock issuable upon the vesting of certain restricted stock units previously granted on December 20, 2017.
Esperion Therapeutics, Inc.
Report date July 13, 2026 · Filed July 13, 2026
Section 16 reporting ended · disclosed 2026-07-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 1
1 source rowRow 1 · 2026-07-13 · Disposition to issuer · Disposed 164,472 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2033-06-15 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-13 · Disposition to issuer · Disposed 21,000 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2034-05-23 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-13 · Disposition to issuer · Disposed 32,500 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2035-05-29 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-13 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions.
F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 08, 2020 Filed Apr 9, 2020 16:05 UTC | Aravive, Inc. ARAV · Entity 114535 | Disposition to issuerCommon Stock | 9,291 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010588 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,201 F1 · shares: The reporting person resigned his position as Chairman of the Board of Directors of Aravive, Inc., effective April 8, 2020, resulting in the forfeiture of 9,291 shares of common stock issuable upon the vesting of certain restricted stock units previously granted on December 20, 2017. Read SEC document |
| January 15, 2020 Filed Jan 16, 2020 21:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 20,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001055726-20-000004 · wf-form4_157920894919990.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-15 F2 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: The vesting schedule for the 20,000 options is as follows: 5,000 shares vested on January 15, 2020; 5,000 shares will vest on January 15, 2021; 5,000 shares will vest on January 15, 2022; 5,000 shares will vest on January 15, 2023. Read SEC document |
| January 15, 2020 Filed Jan 16, 2020 21:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 12,821 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000004 · wf-form4_157920894919990.xml · derivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,821 Underlying: Common Stock · 12,821 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares will vest on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares will vest on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares will vest on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| January 09, 2020 Filed Jan 9, 2020 19:59 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 5,075 | $0.00 Strike: $13.77 | $0.00 |
DisclosureSEC source: 0000899243-20-000912 · doc4.xml · derivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,075 Underlying: Common stock · 5,075 shares Expires 2030-01-08 F1 · shares: The stock option to purchase shares of common stock of Aravive, Inc. (the "Company") vest pro rata on a monthly basis over the next eight months of continuous service commencing February 9, 2020 with full vesting, if not fully vested at such time, on the date of the Company's next annual meeting of stockholders. F1 · derivative.exercise_date: The stock option to purchase shares of common stock of Aravive, Inc. (the "Company") vest pro rata on a monthly basis over the next eight months of continuous service commencing February 9, 2020 with full vesting, if not fully vested at such time, on the date of the Company's next annual meeting of stockholders. F1 · derivative.underlying_shares: The stock option to purchase shares of common stock of Aravive, Inc. (the "Company") vest pro rata on a monthly basis over the next eight months of continuous service commencing February 9, 2020 with full vesting, if not fully vested at such time, on the date of the Company's next annual meeting of stockholders. F1 · balance_after: The stock option to purchase shares of common stock of Aravive, Inc. (the "Company") vest pro rata on a monthly basis over the next eight months of continuous service commencing February 9, 2020 with full vesting, if not fully vested at such time, on the date of the Company's next annual meeting of stockholders. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 16:05 UTC | Aravive, Inc. ARAV · Entity 114535 | Tax withholdingCommon Stock | 2,262 | $11.67 | $26,397.54 |
DisclosureSEC source: 0000899243-19-030048 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,492 F1 · shares: Represents the number of shares withheld to cover tax withholding obligations in connection with the vesting of certain restricted stock units, which were previously reported in Table I following the date of grant. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 16:08 UTC | Aravive, Inc. ARAV · Entity 114535 | SaleCommon Stock | 4,004 | $6.82 | $27,295.27 |
DisclosureSEC source: 0000899243-19-025300 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,754 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units, which were previously reported in Table I following the date of grant. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:50 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 4,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-006914 · edgar.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,967 F1 · shares: The shares vest in full on the earlier of (i) May 29, 2020 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2019. Read SEC document |
| May 10, 2019 Filed May 13, 2019 18:15 UTC | Aravive, Inc. ARAV · Entity 114535 | SaleCommon Stock | 1,192 | $6.11 | $7,283.12 |
DisclosureSEC source: 0000899243-19-013333 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,758 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units, which were previously reported in Table I following the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 16:50 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 116,000 | $0.00 Strike: $5.83 | $0.00 |
DisclosureSEC source: 0000899243-19-005786 · doc4.xml · derivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,000 Underlying: Common Stock · 116,000 shares Expires 2029-02-27 F1 · shares: These options vest pro rata on a monthly basis over 48 months. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 19:53 UTC | Aravive, Inc. ARAV · Entity 114535 | SaleCommon Stock | 990 | $4.14 | $4,098.60 |
DisclosureSEC source: 0000899243-19-002710 · doc4.xml · nonDerivative · entry 3 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,950 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units, which were previously reported in Table I following the date of grant. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 19:53 UTC | Aravive, Inc. ARAV · Entity 114535 | SaleCommon Stock | 969 | $4.14 | $4,011.66 |
DisclosureSEC source: 0000899243-19-002710 · doc4.xml · nonDerivative · entry 2 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,940 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units, which were previously reported in Table I following the date of grant. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 19:53 UTC | Aravive, Inc. ARAV · Entity 114535 | SaleCommon Stock | 204 | $4.14 | $844.56 |
DisclosureSEC source: 0000899243-19-002710 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,909 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units, which were previously reported in Table I following the date of grant. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 20:01 UTC | Aravive, Inc. ARAV · Entity 114535 | SaleCommon Stock | 3,484 | $3.22 | $11,232.42 |
DisclosureSEC source: 0001209191-18-064136 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,113 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 19:59 UTC | Aravive, Inc. ARAV · Entity 114535 | SaleCommon Stock | 11,247 | $3.96 | $44,560.61 |
DisclosureSEC source: 0001209191-18-063590 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,597 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. F2 · balance_after: The number of shares reflects the one-for-six reverse stock split effected by Aravive, Inc. on October 16, 2018. Read SEC document |
| May 24, 2018 Filed May 29, 2018 20:34 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 18,700 | $0.00 Strike: $37.69 | $0.00 |
DisclosureSEC source: 0001179110-18-007618 · edgar.xml · derivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock · 18,700 shares Expires 2028-05-24 F1 · derivative.exercise_date: Vests in equal monthly installments rounded down to the nearest whole share over the 36 months following May 24, 2018, with the balance of the options vesting on the last monthly vesting date which is the third anniversary of May 24, 2018. Read SEC document |
| May 22, 2018 Filed May 23, 2018 17:42 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 9,232 | $1.50 | $13,848.00 |
DisclosureSEC source: 0001209191-18-032687 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,066 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 17:25 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 14,446 | $1.80 | $26,002.80 |
DisclosureSEC source: 0001209191-18-009272 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,298 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 17:07 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 223,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067103 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,744 F1 · shares: Represents the grant of Restricted Stock Units that vest as follows: 25% of the shares vest on each of December 20, 2018, December 20, 2019, December 20, 2020 and December 20, 2021. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 20:15 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 189,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056566 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,744 F1 · shares: Represents the grant of Restricted Stock Units that vest as follows: 50% of the shares vest on each of October 6, 2018 and October 6, 2019. Read SEC document |
| May 11, 2017 Filed May 15, 2017 17:02 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 9,114 | $17.50 | $159,495.00 |
DisclosureSEC source: 0001209191-17-032372 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,744 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 19:34 UTC | Aravive, Inc. VSAR · Entity 114535 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,166 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0001209191-17-015522 · doc4.xml · derivative · entry 3 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,828 Underlying: Common Stock · 5,166 shares Expires 2023-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option become exercisable one year from 12/10/2013; the remainder become exercisable in equal monthly installments over the following three years. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 19:34 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 5,166 | $24.00 | $123,984.00 |
DisclosureSEC source: 0001209191-17-015522 · doc4.xml · nonDerivative · entry 2 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,858 F1 · shares: Shares sold pursuant to 10b5-1 plan. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 19:34 UTC | Aravive, Inc. VSAR · Entity 114535 | Exercise / conversionCommon Stock | 5,166 | $2.53 | $13,069.98 |
DisclosureSEC source: 0001209191-17-015522 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 23, 2017 20:23 UTC | Aravive, Inc. VSAR · Entity 114535 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0001209191-17-014077 · doc4.xml · derivative · entry 6 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,994 Underlying: Common Stock · 8,000 shares Expires 2023-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option become exercisable one year from 12/10/2013; the remainder become exercisable in equal monthly installments over the following three years. Read SEC document |
| February 23, 2017 Filed Feb 23, 2017 20:23 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 8,000 | $20.00 | $160,000.00 |
DisclosureSEC source: 0001209191-17-014077 · doc4.xml · nonDerivative · entry 4 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,858 F1 · shares: Shares sold pursuant to 10b5-1 plan. Read SEC document |
| February 23, 2017 Filed Feb 23, 2017 20:23 UTC | Aravive, Inc. VSAR · Entity 114535 | Exercise / conversionCommon Stock | 8,000 | $2.53 | $20,240.00 |
DisclosureSEC source: 0001209191-17-014077 · doc4.xml · nonDerivative · entry 3 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 20:23 UTC | Aravive, Inc. VSAR · Entity 114535 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0001209191-17-014077 · doc4.xml · derivative · entry 5 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,994 Underlying: Common Stock · 8,000 shares Expires 2023-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option become exercisable one year from 12/10/2013; the remainder become exercisable in equal monthly installments over the following three years. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 20:23 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 8,000 | $18.50 | $148,000.00 |
DisclosureSEC source: 0001209191-17-014077 · doc4.xml · nonDerivative · entry 2 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,858 F1 · shares: Shares sold pursuant to 10b5-1 plan. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 20:23 UTC | Aravive, Inc. VSAR · Entity 114535 | Exercise / conversionCommon Stock | 8,000 | $2.53 | $20,240.00 |
DisclosureSEC source: 0001209191-17-014077 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 17:23 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 6,719 | $13.69 | $91,983.11 |
DisclosureSEC source: 0001209191-17-008073 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,858 F1 · shares: Shares sold pursuant to 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $13.35 to $14.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2017 Filed Feb 2, 2017 20:12 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 6,973 | $13.51 | $94,205.23 |
DisclosureSEC source: 0001209191-17-007335 · doc4.xml · nonDerivative · entry 7 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,577 F1 · shares: Shares sold pursuant to 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $13.30 to $13.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2017 Filed Feb 2, 2017 20:12 UTC | Aravive, Inc. VSAR · Entity 114535 | Exercise / conversionCommon Stock | 4,166 | $2.53 | $10,539.98 |
DisclosureSEC source: 0001209191-17-007335 · doc4.xml · nonDerivative · entry 6 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2017 Filed Feb 2, 2017 20:12 UTC | Aravive, Inc. VSAR · Entity 114535 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,166 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0001209191-17-007335 · doc4.xml · derivative · entry 10 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,994 Underlying: Common Stock · 4,166 shares Expires 2023-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| February 01, 2017 Filed Feb 2, 2017 20:12 UTC | Aravive, Inc. VSAR · Entity 114535 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,576 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0001209191-17-007335 · doc4.xml · derivative · entry 9 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,160 Underlying: Common Stock · 6,576 shares Expires 2023-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| February 01, 2017 Filed Feb 2, 2017 20:12 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 6,576 | $13.95 | $91,735.20 |
DisclosureSEC source: 0001209191-17-007335 · doc4.xml · nonDerivative · entry 5 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,384 F1 · shares: Shares sold pursuant to 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $13.70 to $14.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2017 Filed Feb 2, 2017 20:12 UTC | Aravive, Inc. VSAR · Entity 114535 | Exercise / conversionCommon Stock | 6,576 | $2.53 | $16,637.28 |
DisclosureSEC source: 0001209191-17-007335 · doc4.xml · nonDerivative · entry 4 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 20:12 UTC | Aravive, Inc. VSAR · Entity 114535 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,662 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0001209191-17-007335 · doc4.xml · derivative · entry 8 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,736 Underlying: Common Stock · 10,662 shares Expires 2023-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 20:12 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 5,940 | $14.16 | $84,110.40 |
DisclosureSEC source: 0001209191-17-007335 · doc4.xml · nonDerivative · entry 3 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,384 F1 · shares: Shares sold pursuant to 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $13.70 to $14.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 20:12 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 4,722 | $13.40 | $63,274.80 |
DisclosureSEC source: 0001209191-17-007335 · doc4.xml · nonDerivative · entry 2 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,324 F1 · shares: Shares sold pursuant to 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $12.70 to $13.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 20:12 UTC | Aravive, Inc. VSAR · Entity 114535 | Exercise / conversionCommon Stock | 10,662 | $2.53 | $26,974.86 |
DisclosureSEC source: 0001209191-17-007335 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2017 Filed Jan 31, 2017 20:34 UTC | Aravive, Inc. VSAR · Entity 114535 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,596 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0001209191-17-006522 · doc4.xml · derivative · entry 7 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,398 Underlying: Common Stock · 10,596 shares Expires 2023-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| January 30, 2017 Filed Jan 31, 2017 20:34 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 10,596 | $13.31 | $141,032.76 |
DisclosureSEC source: 0001209191-17-006522 · doc4.xml · nonDerivative · entry 5 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,384 F4 · shares: Shares sold pursuant to 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $12.90 to $13.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2017 Filed Jan 31, 2017 20:34 UTC | Aravive, Inc. VSAR · Entity 114535 | Exercise / conversionCommon Stock | 10,596 | $2.53 | $26,807.88 |
DisclosureSEC source: 0001209191-17-006522 · doc4.xml · nonDerivative · entry 4 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2017 Filed Jan 31, 2017 20:34 UTC | Aravive, Inc. VSAR · Entity 114535 | SaleCommon Stock | 6,674 | $13.85 | $92,434.90 |
DisclosureSEC source: 0001209191-17-006522 · doc4.xml · nonDerivative · entry 3 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,384 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 20:34 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantStock Option (Right to Buy) · Derivative | 144,900 | $0.00 Strike: $14.30 | $0.00 |
DisclosureSEC source: 0001209191-17-006522 · doc4.xml · derivative · entry 6 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,900 Underlying: Common Stock · 144,900 shares Expires 2027-01-26 F6 · derivative.exercise_date: 1/48th of the shares subject to the option become exercisable monthly measured from the date of grant. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 20:34 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006522 · doc4.xml · nonDerivative · entry 2 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,058 F2 · shares: Represents the grant of Restricted Stock Units that vest as follows: 33.33%, 33.33% and 33.34% of the shares subject to the award vest on each of the first, second and third anniversaries of the date of grant, respectively, subject to the officer's continuous service on each applicable vesting date. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 20:34 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 64,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006522 · doc4.xml · nonDerivative · entry 1 Shepard Jay · CIK 0001587788 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,058 F1 · shares: Represents the grant of Restricted Stock Units that vest as follows: 25% of the shares subject to the award vest on each of the first, second, third and fourth anniversaries of the date of grant, respectively, subject to the officer's continuous service on each applicable vesting date. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 17:20 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantRestricted stock · Derivative | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-003119 · a4.xml · derivative · entry 2 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F2 · derivative.exercise_price: Each share of restricted stock represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: All shares of restricted stock vest on 1/17/18. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 17:20 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock option (right to buy) · Derivative | 10,500 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001104659-17-003119 · a4.xml · derivative · entry 1 Shepard Jay · CIK 0001587788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2027-01-17 F1 · derivative.exercise_date: Options to purchase shares of common stock vest in 12 equal monthly installments commencing 1/31/17. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.